Brain Penetration Impeded SERD Efficacy in Breast Cancer Pre-Clinical Models

Stephanie Graff, Director of the Breast Oncology Program at Lifespan Cancer Institute at the Legorreta Cancer Center, shared the post by Sarah Sammons on X:

“[SERDS] demonstrated paradoxical, non-linear response curve with doses exhibiting efficacy than doses Probing this pharmacology in animal models we determined ability of SERDs to cross blood brain barrier and attenuate ER signaling in hypothalamus was differentiator of SERDs.”

Quoting Sarah Sammons’s post:

“Looking forward to seeing full data from Dr McDonnell.

In preclinical models evaluating efficacy of several novel SERDs, Brain Penetration Impeded SERD Efficacy in Breast Cancer Pre-Clinical Models and could differentiate success.”

Title: 8595 Brain Penetration Impedes SERD Efficacy in Breast Cancer Pre-Clinical Models

Authors: S E Wardell, B Chakraborty, S Artham, M A Newlin, M Kirkland, C Chang and D P McDonnell

Stephanie Graff is the Director of the Breast Oncology Program at Lifespan Cancer Institute at the Legorreta Cancer Center at Brown University and co-leader of the Breast Cancer Translational Research Disease Group. She is an Associate Professor of Medicine at the Warren-Alpert School of Medicine. She also serves as a medical advisor to the Dr. Susan Love Foundation for Breast Cancer Research, is an Associate Editor of Cancer Medicine, and chairs the editorial board of Oncology Times.